> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Corcept Reports Promising Survival Data for Ovarian Cancer Drug
- URL: https://www.fdaweb.com/corcept-reports-promising-survival-data-for-ovarian-cancer-drug/
- Published: 2026-01-22T12:00:00.000Z
- Updated: 2026-09-14T15:31:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160529

Corcept Therapeutics says its experimental drug relacorilant met the overall survival primary endpoint in a pivotal Phase 3 trial in patients with platinum-resistant ovarian cancer, marking a key milestone as an NDA for the therapy is under review. The company says the ROSELLA trial showed that patients treated with relacorilant in combination with nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of death compared with patients who received nab-paclitaxel alone. Median overall survival was 16.0 months in the relacorilant arm versus 11.9 months in the control group, it says.

The company previously reported that ROSELLA also met its co-primary endpoint of progression-free survival, with the combination reducing the risk of disease progression by 30%. The results were achieved without requiring selection of patients based on biomarkers and without an increase in treatment-related toxicity, according to the company.

Relacorilant plus nab-paclitaxel was generally well tolerated, Corcept adds, with the type, frequency and severity of adverse events comparable between the combination arm and chemotherapy alone.

Relacorilant is an oral selective glucocorticoid receptor antagonist designed to modulate cortisol activity. In addition to platinum-resistant ovarian cancer, Corcept is studying the drug in other solid tumors, including endometrial, cervical, pancreatic and prostate cancers.

The findings come as Corcept’s NDA for relacorilant as a treatment for platinum-resistant ovarian cancer is under review, with a Prescription Drug User Fee Act target action date of 7/11.